Abstract 535P
Background
Copy number alterations (CNAs) are common consequences of genome instability in lung cancer. Focal amplifications in NKX2-1 copy number (CN) have been frequently observed in non-small cell lung cancer (NSCLC). However, beyond CN gain, little is known about the complete landscape of NKX2-1 CNAs, their clinical significance, and their therapeutic implications in NSCLC.
Methods
Correlations of NKX2-1 expression with EGFR driver mutations and PD-L1 co-expression were studied using immunohistochemistry and PCR from tumors of recruited Filipino patients (n=45). Clinical features of NSCLC with NKX2-1 CNAs were resolved at the tumor and clonal levels using the molecular profiles of LUAD and LUSC participants from TCGA (n=1,130), and deconvoluted single-cell RNA-seq data from Bivona project (n=1,654), respectively.
Results
NKX2-1 expression and CN variations correlated significantly (r= 0.264; p<0.001). However, NKX2-1 CNAs exert a stronger influence on the combined EGFR and PD-L1 status of NSCLC tumors (p<0.05) than expression (p>0.05). NKX2-1 CN gain was prognostic of favorable survival (p=0.018), whereas, NKX2-1 CN loss prognosed worse survival (p=0.041). Mutational architecture in Y-chromosome differentiates the two prognostic groups. There were 19,941 synonymous mutations and 1,408 genome-wide CN perturbations associated with NKX2-1 CNAs. Tumors with NKX2-1 CN gain had higher B cell (p<0.001) and total T cell estimates (p=0.003). NKX2-1 CN loss was associated with colder tumors due to higher M2 macrophage infiltrates (p=0.011) and higher expression of immune checkpoint proteins, CD274 (p=0.025), VTCN1 (p<0.001), and LGALS9 (p=0.002). Lymphocyte marker signature in CN gain was prognostic of longer disease-free survival (p=0.005).
Conclusions
NKX2-1 CNAs are associated with tumors that exhibit clinically diverse characteristics, and with unique oncogenic, immunologic, and prognostic signatures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Science and Technology - Philippine Council for Health Research and Development.
Funding
Department of Science and Technology - Philippine Council on Health Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract